Cellectis S.A. (CLLS)
- Previous Close
1.4600 - Open
1.4600 - Bid --
- Ask --
- Day's Range
1.4600 - 1.5100 - 52 Week Range
1.1000 - 3.3800 - Volume
32,612 - Avg. Volume
343,882 - Market Cap (intraday)
195.707M - Beta (5Y Monthly) 3.38
- PE Ratio (TTM)
-- - EPS (TTM)
-0.4100 - Earnings Date May 26, 2025 - May 30, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.80
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates. The company is developing ALLO-501 to treat large B-cell lymphoma; ALLO-316, an allogeneic engineered CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin's lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics, Inc.; and joint research and collaboration, and investment agreement with AstraZeneca Holdings B.V., as well as with AstraZeneca Ireland Limited. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
www.cellectis.comRecent News: CLLS
View More
Performance Overview: CLLS
Trailing total returns as of 4/25/2025, which may include dividends or other distributions. Benchmark is CAC 40 (^FCHI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CLLS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CLLS
View MoreValuation Measures
Market Cap
201.39M
Enterprise Value
32.55M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.29
Price/Book (mrq)
1.16
Enterprise Value/Revenue
0.78
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-74.69%
Return on Assets (ttm)
-10.37%
Return on Equity (ttm)
-34.08%
Revenue (ttm)
49.22M
Net Income Avi to Common (ttm)
-36.76M
Diluted EPS (ttm)
-0.4100
Balance Sheet and Cash Flow
Total Cash (mrq)
143.25M
Total Debt/Equity (mrq)
67.37%
Levered Free Cash Flow (ttm)
-58.67M